Demographic and clinical characteristics of the patients with SLE-induced abdominal pain.
| SLE-induced Abdominal Pain, n = 132 | Non–SLE-induced Abdominal Pain, n = 81 | p | |
|---|---|---|---|
| Female, n (%) | 108 (81.8) | 73 (90.1) | 0.10 |
| Age at SLE diagnosis, yrs, mean ± SD | 30.95 ± 14.94 | 32.64 ± 14.47 | 0.42 |
| Duration of SLE, mos, median (IQR) | 1.0 (0.0, 24.1) | 1.5 (0.2, 12.0) | 0.31 |
| WBC (× 109/l), median (IQR) | 5.0 (2.7, 6.9) | 5.3 (3.8, 7.2) | 0.38 |
| Hb (g/l), mean ± SD | 89.62 ± 22.80 | 94.21 ± 23.35 | 0.16 |
| PLT (× 109/l), mean ± SD | 159.16 ± 120.42 | 175.22 ± 110.54 | 0.33 |
| CRP (mg/l), mean ± SD | 16.31 ± 22.95 | 14.34 ± 26.20 | 0.56 |
| ESR (mm/h), mean ± SD | 41.13 ± 27.61 | 35.10 ± 23.91 | 0.11 |
| C3 Complement (g/l), mean ± SD | 0.39 ± 0.22 | 0.44 ± 0.22 | 0.08 |
| ALB (g/l), mean ± SD | 27.75 ± 7.09 | 29.26 ± 6.12 | 0.11 |
| SCr (μmol/l), mean ± SD | 128.32 ± 171.06 | 116.85 ± 125.19 | 0.60 |
| IgG (g/l), mean ± SD | 15.20 ± 6.60 | 13.81 ± 5.74 | 0.12 |
| D-dimer (100 μg/l), median (IQR) | 7.6 (5.4, 12.9) | 2.7 (1.5, 4.6) | < 0.01* |
| ACL (IgM/IgG), n (%) | 51 (38.6) | 24 (29.6) | 0.18 |
| Anti-ß2-GP1 (IgG), n (%) | 19 (14.4) | 9 (11.1) | 0.49 |
| ANA, n (%) | 128 (97.0) | 80 (98.8) | 0.40 |
| Anti-dsDNA, n (%) | 98 (74.2) | 64 (79.0) | 0.43 |
| Anti-Sm, n (%) | 37 (28.0) | 29 (35.8) | 0.23 |
| Anti-Ro, n (%) | 87 (65.9) | 50 (61.7) | 0.54 |
| Anti-La, n (%) | 28 (21.2) | 18 (22.2) | 0.86 |
| Anti-U1RNP, n (%) | 43 (32.6) | 30 (37.0) | 0.51 |
| Polyserositis, n (%) | 30 (22.7) | 4 (4.9) | < 0.01* |
| Arthralgia, n (%) | 44 (33.3) | 35 (43.2) | 0.15 |
| Lupus nephritis, n (%) | 96 (72.7) | 52 (64.2) | 0.19 |
| Lupus urinary tract involvement, n (%) | 28 (21.2) | 0 (0) | < 0.01* |
| Pulmonary involvement, n (%) | 21 (15.9) | 13 (16.0) | 0.99 |
| Cardiac involvement, n (%) | 50 (37.9) | 24 (29.6) | 0.22 |
| CNS involvement, n (%) | 22 (16.7) | 11 (13.6) | 0.55 |
| Oral ulcer, n (%) | 51 (38.6) | 16 (19.8) | < 0.01* |
| Ascites, n (%) | 73 (55.3) | 19 (23.5) | < 0.01* |
| Elevated liver enzymes, n (%) | 39 (29.5) | 8 (9.9) | < 0.01* |
| Disease activity (SLEDAI), mean ± SD | 15.75 ± 7.14 | 13.40 ± 5.10 | 0.01* |
| Disease activity (ECLAM), mean ± SD | 6.59 ± 1.84 | 4.44 ± 1.49 | < 0.01* |
↵* Statistically significant. WBC: white blood (cell) count; Hb: hemoglobin; PLT: platelet; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ALB: albumin; SCr: serum creatinine; IgG: immunoglobulin G; ACL: anticardiolipin antibodies; CNS: central nervous system; IQR: interquartile range; SLE: systemic lupus erythematosus; ANA: antinuclear antibody; SLEDAI: SLE Disease Activity Index; ECLAM: European Consensus Lupus Activity Measurement.